OncoCyte Corp Market Cap ($90.37 Million)
Market Cap & Net Worth: OncoCyte Corp (OCX)
OncoCyte Corp market cap. OncoCyte Corp (NASDAQ:OCX) has a market capitalization of $90.37 Million ($90.37 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #19386 globally and #4469 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OncoCyte Corp's stock price $3.16 by its total outstanding shares 28599300 (28.60 Million). Also see cash efficiency ratio of OncoCyte Corp for how efficiently the company converts equity into cash flow.
OncoCyte Corp Market Cap History (2015–2025)
OncoCyte Corp market cap history from 2015 to 2025. Data shows change from $3.57 Billion to $90.37 Million (-33.99% CAGR). Check today's stock price for OncoCyte Corp for real-time trading data and today's change.
Index Memberships
OncoCyte Corp is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #541 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1857 of 3165 |
Weight: OncoCyte Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OncoCyte Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OncoCyte Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is OncoCyte Corp growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
36.19x
OncoCyte Corp's market cap is 36.19 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.29 Billion | $16.00K | -$22.33 Million | 80435.53x | N/A |
| 2020 | $1.37 Billion | $1.22 Million | -$29.93 Million | 1124.22x | N/A |
| 2021 | $1.24 Billion | $7.73 Million | -$64.10 Million | 160.63x | N/A |
| 2022 | $183.55 Million | $958.00K | -$73.44 Million | 191.60x | N/A |
| 2023 | $71.50 Million | $1.50 Million | -$27.78 Million | 47.57x | N/A |
| 2024 | $68.07 Million | $1.88 Million | -$60.66 Million | 36.19x | N/A |
Competitor Companies of OCX by Market Capitalization
Companies near OncoCyte Corp in the global market cap rankings as of November 4, 2026. Also see OncoCyte Corp assets under control for a full breakdown of the balance sheet.
Key companies related to OncoCyte Corp by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #142 globally with a market cap of $162.54 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #479 globally with a market cap of $56.02 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #546 globally with a market cap of $48.96 Billion USD ( CN¥334.59 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $698.34 |
| #142 | Danaher Corporation | NYSE:DHR | $162.54 Billion | $230.11 |
| #479 | Natera Inc | NASDAQ:NTRA | $56.02 Billion | $388.63 |
| #546 | WuXi AppTec Co Ltd | SHG:603259 | $48.96 Billion | CN¥135.28 |
Market Capitalization of OncoCyte Corp (2015–2025)
Market capitalization of OncoCyte Corp from 2015 to today. Between 2015 and today, OncoCyte Corp's market cap moved from $3.57 Billion to $ 90.37 Million, with a yearly change of -33.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $90.37 Million | +32.77% |
| 2024 | $68.07 Million | -4.80% |
| 2023 | $71.50 Million | -61.05% |
| 2022 | $183.55 Million | -85.21% |
| 2021 | $1.24 Billion | -9.21% |
| 2020 | $1.37 Billion | +6.22% |
| 2019 | $1.29 Billion | +63.04% |
| 2018 | $789.34 Million | -70.32% |
| 2017 | $2.66 Billion | -34.04% |
| 2016 | $4.03 Billion | +12.80% |
| 2015 | $3.57 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of OncoCyte Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $90.37 Million USD |
| MoneyControl | $90.37 Million USD |
| MarketWatch | $90.37 Million USD |
| marketcap.company | $90.37 Million USD |
| Reuters | $90.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more